EUVIMEDEUVIMED entdecken
Crossref

Psoriatic Arthritis

Seham R. Alunizi, AlRabbab AlShanqeeti, Khalidah A. Alenzi, Ibrahim Abdulrazag Al-Homood

Annals of Rheumatology and Autoimmunity · 2022

DOI: 10.4103/ara.ara_14_22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Rheumatology and Autoimmunity, 2022. Verfasst von Seham R. Alunizi und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractBibliografische AngabenZitieren

Abstract (Originalsprache)

Objectives

Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis. In this study, we aimed to assess clinical features and the response rates to various biological agents among patients with PsA in the Kingdom of Saudi Arabia. Materials and Methods: A retrospective study where 39 patients diagnosed with PsA based on ClASsification criteria for PsA criteria for the period 2015–2019, were recruited from rheumatology outpatient clinics at KFMC, Riyadh, Saudi Arabia.

Results

Thirty-nine PsA patients (31 females [79.5%] and eight males [20.5%]) were reviewed. The median age at disease onset was 36 years (ranging from 20 to 61 years). The median disease duration was 3 years. Peripheral arthritis reported in 92% and axial involvement in 28.2% of our patients. Fifteen percent of our patients developed enthesitis, whereas 12.5% had dactylitis. The mean duration for adalimumab (ADA) as a first-line treatment was 104 weeks, whereas etanercept (ETA) was 120 weeks. However, ADA had the longest duration in the second-line therapy (177 weeks), and secukinumab (SEC) had the longest duration (209 weeks) in the third-line therapy. ADA was discontinued in 76.9% of our patients due to inefficacy, whereas the most adverse events were reported with SEC and ETA (7.1%).

Conclusion

Our study provided insights on the demographics, characteristics, and responses to various biological treatments of PsA patients in Saudi Arabia.

Zitieren

APA

Alunizi, S. R., AlShanqeeti, A., Alenzi, K. A., & Al-Homood, I. A. (2022). Psoriatic Arthritis. Annals of Rheumatology and Autoimmunity. https://doi.org/10.4103/ara.ara_14_22

Vancouver

Alunizi SR, AlShanqeeti A, Alenzi KA, Al-Homood IA. Psoriatic Arthritis. Annals of Rheumatology and Autoimmunity. 2022. doi:10.4103/ara.ara_14_22

BibTeX
@article{Alunizi2022,
  author = {Alunizi, Seham R. and AlShanqeeti, AlRabbab and Alenzi, Khalidah A. and Al-Homood, Ibrahim Abdulrazag},
  title = {Psoriatic Arthritis},
  journal = {Annals of Rheumatology and Autoimmunity},
  year = {2022},
  doi = {10.4103/ara.ara_14_22}
}
Kostenlos starten →